Fax: (713) 794-1800
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine
Article first published online: 23 JAN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 5, pages 1041–1048, 1 March 2009
How to Cite
Garcia, M., Romaguera, J. E., Inamdar, K. V., Rassidakis, G. Z. and Medeiros, L. J. (2009), Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer, 115: 1041–1048. doi: 10.1002/cncr.24141
Fax: (713) 794-1800
- Issue published online: 18 FEB 2009
- Article first published online: 23 JAN 2009
- Manuscript Accepted: 29 SEP 2008
- Manuscript Received: 28 JUL 2008
- 1Mantle cell lymphoma. In: JaffeES, HarrisNL, SteinH, VardimanJW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 168-170., , , et al.
- 8Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma—results of a prospective randomized trial of the European MCL Network. Blood. 2005; 105: 2677-2684., , , et al.
- 9The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulphan, melphalan, and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007; 86: 101-105., , , et al.
- 18Blastoid mantle cell lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-hyperCVAD alternating with R-methotrexate/cytarabine (M/A) [ASH Annual Meeting Abstracts]. Blood. 2006; 108. Abstract 2749., , , et al.